Medigene AG of Germany has appointed Selwyn Ho as its new chief executive, effective 25 July, to succeed Dolores Schendel. Dr Schendel will continue as chief scientific officer and head of research and development. Dr Ho is joining Medigene from Connect Biopharma Holding Ltd, a company developing therapies against chronic inflammatory diseases, where he was chief business officer. He is also an executive-in-residence at New Rhein Healthcare Investors LLC, a US venture capital firm focused on repurposed assets.
Medigene announced the appointment on 12 May 2022.
Copyright 2022 Evernow Publishing Ltd